266 related articles for article (PubMed ID: 23824742)
61. Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.
Rajule R; Bryant VC; Lopez H; Luo X; Natarajan A
Bioorg Med Chem; 2012 Apr; 20(7):2227-34. PubMed ID: 22386982
[TBL] [Abstract][Full Text] [Related]
62. Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X
Roy MJ; Vom A; Okamoto T; Smith BJ; Birkinshaw RW; Yang H; Abdo H; White CA; Segal D; Huang DCS; Baell JB; Colman PM; Czabotar PE; Lessene G
J Med Chem; 2021 May; 64(9):5447-5469. PubMed ID: 33904752
[TBL] [Abstract][Full Text] [Related]
63. S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak.
Song T; Chang X; Zhang Z; Liu Y; Shen X
J Pharmacol Sci; 2012; 119(4):330-40. PubMed ID: 22814102
[TBL] [Abstract][Full Text] [Related]
64. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
[TBL] [Abstract][Full Text] [Related]
65. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
Hann CL; Daniel VC; Sugar EA; Dobromilskaya I; Murphy SC; Cope L; Lin X; Hierman JS; Wilburn DL; Watkins DN; Rudin CM
Cancer Res; 2008 Apr; 68(7):2321-8. PubMed ID: 18381439
[TBL] [Abstract][Full Text] [Related]
66. Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.
Loriot Y; Mordant P; Dugue D; Geneste O; Gombos A; Opolon P; Guegan J; Perfettini JL; Pierre A; Berthier LK; Kroemer G; Soria JC; Depil S; Deutsch E
Cell Death Dis; 2014 Sep; 5(9):e1423. PubMed ID: 25232677
[TBL] [Abstract][Full Text] [Related]
67. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
[TBL] [Abstract][Full Text] [Related]
68. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
[TBL] [Abstract][Full Text] [Related]
69. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
Premkumar DR; Jane EP; DiDomenico JD; Vukmer NA; Agostino NR; Pollack IF
J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246
[TBL] [Abstract][Full Text] [Related]
70. A brewing understanding of the regulation of Bax function by Bcl-xL and Bcl-2.
Renault TT; Dejean LM; Manon S
Mech Ageing Dev; 2017 Jan; 161(Pt B):201-210. PubMed ID: 27112371
[TBL] [Abstract][Full Text] [Related]
71. Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization.
Buron N; Porceddu M; Brabant M; Desgué D; Racoeur C; Lassalle M; Péchoux C; Rustin P; Jacotot E; Borgne-Sanchez A
PLoS One; 2010 Mar; 5(3):e9924. PubMed ID: 20360986
[TBL] [Abstract][Full Text] [Related]
72. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
73. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
74. Bcl-2 inhibition to overcome memory cell barriers in transplantation.
Cippà PE; Gabriel SS; Kraus AK; Chen J; Wekerle T; Guimezanes A; Wüthrich RP; Fehr T
Am J Transplant; 2014 Feb; 14(2):333-42. PubMed ID: 24472193
[TBL] [Abstract][Full Text] [Related]
75. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
[TBL] [Abstract][Full Text] [Related]
76. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL.
Yosef R; Pilpel N; Tokarsky-Amiel R; Biran A; Ovadya Y; Cohen S; Vadai E; Dassa L; Shahar E; Condiotti R; Ben-Porath I; Krizhanovsky V
Nat Commun; 2016 Apr; 7():11190. PubMed ID: 27048913
[TBL] [Abstract][Full Text] [Related]
77. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
78. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
79. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
[TBL] [Abstract][Full Text] [Related]
80. Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak.
Wang C; Youle RJ
Oncogene; 2012 Jun; 31(26):3177-89. PubMed ID: 22056880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
